Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
ApexOnco Front Page
Recent articles
After setbacks, cema-cel might have a path to approval in lymphoma.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
The company’s AN9025 will shortly enter phase 1.
Though lung cancer looks promising a partner is now needed.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
But the group still hopes to get IGV-001 approved based on overall survival data.
